Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02521545 · ClinicalTrials.gov registry record · Phase 1
Single-Dose Study of a New Formulation of BIIB061
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02521545 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 8 participants.
The verdict
NCT02521545, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the pharmacokinetic (PK) profile of BIIB061 in the new oral formulation in the fasted state in healthy male and female volunteers. The secondary objective of this study is to evaluate the safety and tolerability of BIIB061 in the new formulation in this study population.
Interventions
- DRUG BIIB061
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02521545
The ClinicalTrials.gov registry entry for NCT02521545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIB061 is the first listed.
NCT02521545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02521545 about?
NCT02521545 is a clinical study titled "Single-Dose Study of a New Formulation of BIIB061". The primary objective of the study is to assess the pharmacokinetic (PK) profile of BIIB061 in the new oral formulation in the fasted state in healthy male and female volunteers. The secondary objective of this study is to evaluate the safety and tolerability of BIIB061 in the new formulation in thi...
What is the current status of trial NCT02521545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-07. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02521545?
The interventions under investigation include: BIIB061 (DRUG).
Who is sponsoring clinical trial NCT02521545?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.